Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients Does not Prevent Infective Complications and Infections-related Deaths - Scorecard - MDSpire
Advertisement
Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients Does not Prevent Infective Complications and Infections-related Deaths
Clinical Scorecard: Efficacy of Levofloxacin Prophylaxis in Preventing Infectious Complications and Mortality in Pediatric and Young Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
At a Glance
Category
Detail
Condition
Infectious complications in pediatric and young adult allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients
Key Mechanisms
Levofloxacin (LVX) prophylaxis aims to reduce bacterial infections and febrile neutropenia by broad-spectrum antibacterial activity; impact on gut microbiota and antibiotic resistance evaluated
Target Population
Pediatric and young adult patients undergoing allo-HCT
Care Setting
Pediatric transplant unit in a tertiary care hospital
Key Highlights
LVX prophylaxis did not reduce incidence of acute graft-versus-host disease, bloodstream infections, or infection-related mortality in allo-HCT recipients.
Patients receiving LVX prophylaxis showed higher rates of quinolone-resistant bacterial strains during infections.
LVX prophylaxis was associated with alterations in gut microbiota composition, including reduced abundance of Blautia, Enterococcus, and Actinomyces at neutrophil engraftment.
Guideline-Based Recommendations
Diagnosis
Monitor for febrile neutropenia and bloodstream infections in pediatric allo-HCT recipients.
Management
Routine use of systemic antibacterial prophylaxis with levofloxacin is weakly recommended against in children and young adults undergoing allo-HCT due to low evidence of benefit.
Prompt empirical antibiotic treatment should be initiated upon febrile neutropenia rather than routine prophylaxis.
Monitoring & Follow-up
Surveillance for antibiotic-resistant bacterial strains during infections is advised, especially in patients receiving quinolone prophylaxis.
Monitor gut microbiota changes as they may impact transplant outcomes.
Risks
Increased prevalence of quinolone-resistant bacterial infections with LVX prophylaxis.
Potential gut microbiota dysbiosis associated with antibiotic prophylaxis.
Possible severe adverse drug effects of quinolones in pediatric patients warrant cautious use.
Patient & Prescribing Data
143 pediatric and young adult patients undergoing 144 allo-HCT procedures
Levofloxacin prophylaxis did not improve survival or reduce infection rates but increased antibiotic resistance and altered gut microbiota composition.
Clinical Best Practices
Avoid routine levofloxacin prophylaxis in pediatric allo-HCT recipients due to lack of demonstrated benefit and risk of resistance.
Implement antimicrobial stewardship programs to guide prophylaxis and empirical therapy decisions.
Use prompt empirical antibiotic therapy upon febrile neutropenia rather than prophylaxis.
Consider monitoring gut microbiota as part of transplant outcome assessment.
